A major shift is underway in diagnosing Alzheimer's disease, moving from subjective clinical assessment to objective biological evidence. The condition, the most common cause of dementia, often presents first in primary care settings. Clinicians must distinguish it from other types of dementia, such as vascular, Lewy body, and frontotemporal.
The diagnostic pathway now begins with standard lab work and imaging. Computed tomography and MRI are used to rule out other causes like strokes or tumors. More definitive diagnosis relies on specialized tests: amyloid and tau PET scans, and cerebrospinal fluid analysis for beta amyloid and phosphorylated tau.
Critically, blood-based biomarkers are poised to expand access to diagnosis, especially where PET scans or dementia specialists are scarce. Tests measuring proteins like amyloid beta 42/40 and phosphorylated tau can support diagnosis in high-risk patients. However, experts caution these are not for general population screening.
The rise of amyloid-modifying therapies creates a new urgency for acute care teams. They must recognize treatment side effects, known as amyloid-related imaging abnormalities, which include brain swelling and bleeding. This is crucial when treating patients with stroke, as those on the therapy face higher hemorrhage risk.
Experts conclude that future dementia care must prioritize primary care screening, equitable access to biomarker testing, and timely specialty referral to guide patients through this new diagnostic era.